| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5289 | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1330 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 662 | 2021 |
| Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint … DF Hanley, RE Thompson, M Rosenblum, G Yenokyan, K Lane, N McBee, ... The Lancet 393 (10175), 1021-1032, 2019 | 653 | 2019 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 257 | 2021 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 174 | 2021 |
| Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer … S Toback, E Galiza, C Cosgrove, J Galloway, AL Goodman, PA Swift, ... The Lancet Respiratory Medicine 10 (2), 167-179, 2022 | 133 | 2022 |
| Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a … APS Munro, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, ... The Lancet Infectious Diseases 22 (8), 1131-1141, 2022 | 131 | 2022 |
| Negative capsule endoscopy in patients with obscure GI bleeding predicts low rebleeding rates J Macdonald, V Porter, D McNamara Gastrointestinal endoscopy 68 (6), 1122-1127, 2008 | 127 | 2008 |
| SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group … JL Alexander, GW Moran, DR Gaya, T Raine, A Hart, NA Kennedy, ... The Lancet Gastroenterology & Hepatology 6 (3), 218-224, 2021 | 118 | 2021 |
| Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers M Logan, K Gkikas, V Svolos, B Nichols, S Milling, DR Gaya, JP Seenan, ... Alimentary Pharmacology & Therapeutics 51 (10), 935-947, 2020 | 68 | 2020 |
| Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients N Chanchlani, S Lin, D Chee, B Hamilton, R Nice, Z Arkir, C Bewshea, ... Journal of Crohn's and Colitis 16 (3), 389-397, 2022 | 48 | 2022 |
| Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort N Plevris, CS Chuah, RM Allen, ID Arnott, PN Brennan, S Chaudhary, ... Journal of Crohn's and Colitis 13 (9), 1111-1120, 2019 | 42 | 2019 |
| Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study S Sebastian, GJ Walker, NA Kennedy, TE Conley, KV Patel, ... The Lancet Gastroenterology & Hepatology 6 (4), 271-281, 2021 | 29 | 2021 |
| Small bowel lymphangiectasia and angiodysplasia: a positive association; novel clinical marker or shared pathophysiology? J Macdonald, V Porter, NW Scott, D McNamara Journal of clinical gastroenterology 44 (9), 610-614, 2010 | 25 | 2010 |
| Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and … Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ... The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023 | 24 | 2023 |
| Real‐world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort N Plevris, J Fulforth, S Siakavellas, A Robertson, R Hall, A Tyler, ... Journal of gastroenterology and hepatology 36 (8), 2067-2075, 2021 | 19 | 2021 |
| Pathogenesis of musculoskeletal deficits in children and adults with inflammatory bowel disease L Steell, SR Gray, RK Russell, J MacDonald, JP Seenan, SC Wong, ... Nutrients 13 (8), 2899, 2021 | 15 | 2021 |
| Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF … N Chanchlani, S Lin, MK Auth, CL Lee, H Robbins, S Looi, SV Murugesan, ... Alimentary Pharmacology & Therapeutics 56 (8), 1250-1263, 2022 | 10 | 2022 |
| The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis M Perry, A Abdullah, M Frleta, J MacDonald, A McGucken Therapeutic advances in musculoskeletal disease 12, 1759720X20904850, 2020 | 10 | 2020 |
